Genetics and Smoking

Current Addiction Reports

Volumn 1, Issue 1, 2014, Pages 75-82

  Loukola, Anu ^a   Hällfors, Jenni ^a   Korhonen, Tellervo ^a   Kaprio, Jaakko ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Addiction; Genes; Genome wide association; Nicotine; Nicotine metabolism; Nicotinic receptors; Tobacco

Indexed keywords

EID: 84908143243     PISSN: None     EISSN: 21962952     Source Type: Journal    
DOI: 10.1007/s40429-013-0006-3     Document Type: Review

References (83)

1. USDHHS. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
2. Hukkanen J, Jacob 3rd P, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev. 2005;57:79–115.
3. Berridge MS, Apana SM, Nagano KK, Berridge CE, Leisure GP, Boswell MV. Smoking produces rapid rise of [11C]nicotine in human brain. Psychopharmacology (Berl). 2010;209:383–94.
4. Buisson B, Bertrand D. Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol Sci. 2002;23:130–6.
5. Lessov-Schlaggar CN, Pergadia ML, Khroyan TV, Swan GE. Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol. 2008;75:178–95.
6. Rose JE, Broms U, Korhonen T, Dick DM, Kaprio J. Genetics of smoking behavior. In: Kim YK, editor. Handbook of behavior genetics. New York: Springer; 2009. p. 411–32.
7. Tobacco and Genetics Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet. 2010;42:441–7. Papers 7–9, published back-to-back in Nature Genetics in 2010, jointly looked at four smoking behavior phenotypes in a GWAS meta-analysis comprising approximately 140 0000 subjects.
8. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L, et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet. 2010;42:436–40. Papers 7–9, published back-to-back in Nature Genetics in 2010, jointly looked at four smoking behavior phenotypes in a GWAS meta-analysis comprising approximately 140 0000 subjects.
9. Thorgeirsson TE, Gudbjartsson DF, Surakka I, Vink JM, Amin N, Geller F, et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet. 2010;42:448–53. Papers 7–9, published back-to-back in Nature Genetics in 2010, jointly looked at four smoking behavior phenotypes in a GWAS meta-analysis comprising approximately 140 0000 subjects.
10. Miyazawa A, Fujiyoshi Y, Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature. 2003;423:949–55.
11. Dajas-Bailador F, Wonnacott S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends Pharmacol Sci. 2004;25:317–24.
12. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 1997;20:92–8.
13. Nestler EJ. Is there a common molecular pathway for addiction? Nat Neurosci. 2005;8:1445–9.
14. Schilstrom B, Fagerquist MV, Zhang X, Hertel P, Panagis G, Nomikos GG, et al. Putative role of presynaptic alpha7* nicotinic receptors in nicotine stimulated increases of extracellular levels of glutamate and aspartate in the ventral tegmental area. Synapse. 2000;38:375–83.
15. Riedel G, Platt B, Micheau J. Glutamate receptor function in learning and memory. Behav Brain Res. 2003;140:1–47.
16. Cooper E, Couturier S, Ballivet M. Pentameric structure and subunit stoichiometry of a neuronal nicotinic acetylcholine receptor. Nature. 1991;350:235–8.
17. Collins AC, Salminen O, Marks MJ, Whiteaker P, Grady SR. The road to discovery of neuronal nicotinic cholinergic receptor subtypes. Handb Exp Pharmacol. 2009;192:85–112.
18. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008;452:638–42.
19. David SP, Hamidovic A, Chen GK, Bergen AW, Wessel J, Kasberger JL, et al. Genome-wide meta-analyses of smoking behaviors in African Americans. Transl Psychiatry. 2012;2:e119.
20. Yoon D, Kim YJ, Cui WY, Van der Vaart A, Cho YS, Lee JY, et al. Large-scale genome-wide association study of Asian population reveals genetic factors in FRMD4A and other loci influencing smoking initiation and nicotine dependence. Hum Genet. 2012;131:1009–21.
21. Saccone NL, Culverhouse RC, Schwantes-An TH, Cannon DS, Chen X, Cichon S, et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet. 2010;6:e1001053. In this paper the authors diligently scrutinized the 15q25 smoking locus, and dissected several independent loci contributing to smoking behavior, suggesting a high level of genetic complexities within this locus.
22. Bierut LJ. Genetic vulnerability and susceptibility to substance dependence. Neuron. 2011;69(4):618–27.
23. Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ. Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature. 2011;471:597–601. This sophisticated paper reveals that, at least in rodents, CHRNA5 is crucial in inducing an inhibitory motivational signal that acts to limit nicotine intake.
24. Saccone NL, Wang JC, Breslau N, Johnson EO, Hatsukami D, Saccone SF, et al. The CHRNA5-CHRNA3-CHRNB4 nicotinic receptor subunit gene cluster affects risk for nicotine dependence in African-Americans and in European-Americans. Cancer Res. 2009;69:6848–56.
25. Li MD, Yoon D, Lee JY, Han BG, Niu T, Payne TJ, et al. Associations of variants in CHRNA5/A3/B4 gene cluster with smoking behaviors in a Korean population. PLoS One. 2010;5:e12183.
26. Hallfors J, Loukola A, Pitkaniemi J, Broms U, Mannisto S, Salomaa V, et al. Scrutiny of the CHRNA5-CHRNA3-CHRNB4 smoking behavior locus reveals a novel association with alcohol use in a Finnish population based study. Int J Mol Epidemiol Genet. 2013;4:109–19.
27. Broms U, Wedenoja J, Largeau MR, Korhonen T, Pitkaniemi J, Keskitalo-Vuokko K, et al. Analysis of detailed phenotype profiles reveals CHRNA-CHRNA3-CHRNB4 gene cluster association with several nicotine dependence traits. Nicotine Tob Res. 2012;14:720–33. doi:10.1093/ntr/ntr283.
28. Gabrielsen ME, Romundstad P, Langhammer A, Krokan HE, Skorpen F. Association between a 15q25 gene variant, nicotine-related habits, lung cancer and COPD among 56 307 individuals from the HUNT study in Norway. Eur J Hum Genet. 2013;21:1293–9.
29. Lips EH, Gaborieau V, McKay JD, Chabrier A, Hung RJ, Boffetta P, et al. Association between a 15q25 gene variant, smoking quantity and tobacco-related cancers among 17 000 individuals. Int J Epidemiol. 2010;39:563–77.
30. Walsh KM, Amos CI, Wenzlaff AS, Gorlov IP, Sison JD, Wu X, et al. Association study of nicotinic acetylcholine receptor genes identifies a novel lung cancer susceptibility locus near CHRNA1 in African-Americans. Oncotarget. 2012;3:1428–38.
31. Walsh KM, Gorlov IP, Hansen HM, Wu X, Spitz MR, Zhang H, et al. Fine-mapping of the 5p15.33, 6p22.1-p21.31, and 15q25.1 regions identifies functional and histology-specific lung cancer susceptibility loci in African-Americans. Cancer Epidemiol Biomarkers Prev. 2013;22:251–60.
32. Kapoor M, Wang JC, Bertelsen S, Bucholz K, Budde JP, Hinrichs A, et al. Variants located upstream of CHRNB4 on chromosome 15q25.1 are associated with age at onset of daily smoking and habitual smoking. PLoS One. 2012;7:e33513.
33. Stephens SH, Hartz SM, Hoft NR, Saccone NL, Corley RC, Hewitt JK, et al. Distinct loci in the CHRNA5/CHRNA3/CHRNB4 gene cluster are associated with onset of regular smoking. Genet Epidemiol. 2013;37:846–59.
34. Hartz SM, Short SE, Saccone NL, Culverhouse R, Chen L, Schwantes-An TH, et al. Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers. Arch Gen Psychiatry. 2012;69:854–60. A large meta-analysis presenting evidence for a gene by environment (G × E) interaction at the 15q25 locus.
35. Sherva R, Kranzler HR, Yu Y, Logue MW, Poling J, Arias AJ, et al. Variation in nicotinic acetylcholine receptor genes is associated with multiple substance dependence phenotypes. Neuropsychopharmacology. 2010;35:1921–31.
36. Foulds J, Ramstrom L, Burke M, Fagerström K. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control. 2003;12:349–59.
37. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The fagerström test for nicotine dependence: a revision of the fagerström tolerance questionnaire. Br J Addict. 1991;86:1119–27.
38. Rice JP, Hartz SM, Agrawal A, Almasy L, Bennett S, Breslau N, et al. CHRNB3 is more strongly associated with fagerström test for cigarette dependence-based nicotine dependence than cigarettes per day: phenotype definition changes genome-wide association studies results. Addiction. 2012;107:2019–28.
39. Cui WY, Wang S, Yang J, Yi SG, Yoon D, Kim YJ, et al. Significant association of CHRNB3 variants with nicotine dependence in multiple ethnic populations. Mol Psychiatry. 2013;18:1149–51.
40. Han S, Gelernter J, Luo X, Yang BZ. Meta-analysis of 15 genome-wide linkage scans of smoking behavior. Biol Psychiatry. 2010;67:12–9. This paper summarizes the linkage analysis literature, which may be of relevance when searching for rare variants in families.
41. Xie P, Kranzler HR, Krauthammer M, Cosgrove KP, Oslin D, Anton RF, et al. Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry. 2011;70:528–36.
42. Haller G, Druley T, Vallania FL, Mitra RD, Li P, Akk G, et al. Rare missense variants in CHRNB4 are associated with reduced risk of nicotine dependence. Hum Mol Genet. 2012;21:647–55.
43. Wang J, Li MD. Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. Neuropsychopharmacology. 2010;35:702–19.
44. Petrovsky N, Quednow BB, Ettinger U, Schmechtig A, Mossner R, Collier DA, et al. Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology. 2010;35:1429–39.
45. Hong LE, Yang X, Wonodi I, Hodgkinson CA, Goldman D, Stine OC, et al. A CHRNA5 allele related to nicotine addiction and schizophrenia. Genes Brain Behav. 2011;10:530–5.
46. Bakanidze G, Roinishvili M, Chkonia E, Kitzrow W, Richter S, Neumann K, et al. Association of the nicotinic receptor alpha7 subunit gene (CHRNA7) with schizophrenia and visual backward masking. Front Psychiatry. 2013;4:133.
47. Cross-Disorder Group of the Psychiatric Genomics Consortium, Genetic Risk Outcome of Psychosis (GROPU) Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. The Lancet. 2013;381:1371–79.
48. Patkar AA, Gopalakrishnan R, Lundy A, Leone FT, Certa KM, Weinstein SP. Relationship between tobacco smoking and positive and negative symptoms in schizophrenia. J Nerv Ment Dis. 2002;190:604–10.
49. Loukola A, Wedenoja J, Keskitalo-Vuokko K, Broms U, Korhonen T, Ripatti S, et al. Genome-wide association study on detailed profiles of smoking behavior and nicotine dependence in a twin sample. Mol Psychiatry. 2013. doi:10.1038/mp.2013.72. This is the first paper to present data supporting the involvement of the neuregulin signaling pathway in nicotine dependence. The association between nicotine dependence and a neuregulin receptor, ERBB4, is supported by convergent evidence from linkage studies and by replication in an independent sample. Future support comes from behavioral mouse models (see Ref. [50], below).
50. Turner JR, Ray R, Lee B, Everett L, Xiang J, Jepson C, et al. Evidence from mouse and man for a role of neuregulin 3 in nicotine dependence. Mol Psychiatry. 2013. doi:10.1038/mp.2013.104. This paper nicely demonstrates that both ErbB4 and NRG3 (Neuregulin 3) expression increases during nicotine exposure and withdrawal in a mouse model. Further, withdrawal-induced anxiety is abolished both in mice with a knock-down mutation in Nrg3, and in mice treated with an ErbB4 inhibitor, suggesting that the neuregulin signaling pathway is essential in the anxiety effects of nicotine withdrawal. The authors also show that NRG3 SNPs associate with smoking cessation success in a clinical trial.
51. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res. 2003;284:14–30.
52. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci. 2008;9:437–52.
53. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71:877–92.
54. Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet. 2003;72:83–7.
55. Harrison PJ, Law AJ. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry. 2006;60:132–40.
56. Chen PL, Avramopoulos D, Lasseter VK, McGrath JA, Fallin MD, Liang KY, et al. Fine mapping on chromosome 10q22-q23 implicates Neuregulin 3 in schizophrenia. Am J Hum Genet. 2009;84:21–34.
57. Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R. The involvement of ErbB4 with schizophrenia: association and expression studies. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:142–8.
58. Norton N, Moskvina V, Morris DW, Bray NJ, Zammit S, Williams NM, et al. Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:96–101.
59. Law AJ, Kleinman JE, Weinberger DR, Weickert CS. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet. 2007;16:129–41.
60. Savonenko AV, Melnikova T, Laird FM, Stewart KA, Price DL, Wong PC. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci U S A. 2008;105:5585–90.
61. Dejaegere T, Serneels L, Schafer MK, Van Biervliet J, Horre K, Depboylu C, et al. Deficiency of Aph1B/C-gamma-secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment. Proc Natl Acad Sci U S A. 2008;105:9775–80.
62. Diagnostic and statistical manual of mental disorders: DSM-IV (4th edition). American Psychiatric Association: Washington, 1994.
63. Hatzimanolis A, McGrath JA, Wang R, Li T, Wong PC, Nestadt G, et al. Multiple variants aggregate in the neuregulin signaling pathway in a subset of schizophrenia patients. Transl Psychiatry. 2013;3:e264.
64. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther. 1997;282:1608–14.
65. Mwenifumbo JC, Tyndale RF. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics. 2007;8:1385–402.
66. Ho MK, Tyndale RF. Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J. 2007;7:81–98.
67. Gold AB, Lerman C. Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. Hum Genet 2012.
68. Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, Benowitz NL. Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics. 2009;19:388–98.
69. Benowitz NL, Hukkanen J, Jacob 3rd P. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009;192:29–60.
70. Zhu AZ, Renner CC, Hatsukami DK, Swan GE, Lerman C, Benowitz NL, et al. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev. 2013;22:708–18.
71. Dempsey D, Tutka P, Jacob 3rd P, Allen F, Schoedel K, Tyndale RF, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther. 2004;76:64–72.
72. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology. 2003;45:122–32.
73. Bloom AJ, Baker TB, Chen LS, Breslau N, Hatsukami D, Bierut LJ, et al. Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. Hum Mol Genet 2013.
74. Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, et al. Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction. 2013. doi:10.1111/add.12353.
75. Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. J Natl Cancer Inst. 2011;103:1342–6.
76. Keskitalo K, Broms U, Heliovaara M, Ripatti S, Surakka I, Perola M, et al. Association of serum cotinine level with a cluster of three nicotinic acetylcholine receptor genes (CHRNA3/CHRNA5/CHRNB4) on chromosome 15. Hum Mol Genet. 2009;18:4007–12.
77. Munafò MR, Timofeeva MN, Morris RW, Prieto-Merino D, Sattar N, Brennan P, et al. Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J Natl Cancer Inst. 2012;104:740–8.
78. Ware J, Munafò M. The genetic basis of heaviness of smoking: Results from a genome-wide meta-analysis. Boston: SRNT Annual Meeting; 2013.
79. Dick DM, Viken R, Purcell S, Kaprio J, Pulkkinen L, Rose RJ. Parental monitoring moderates the importance of genetic and environmental influences on adolescent smoking. J Abnorm Psychol. 2007;116:213–8.
80. Timberlake DS, Rhee SH, Haberstick BC, Hopfer C, Ehringer M, Lessem JM, et al. The moderating effects of religiosity on the genetic and environmental determinants of smoking initiation. Nicotine Tob Res. 2006;8:123–33.
81. Chen LS, Johnson EO, Breslau N, Hatsukami D, Saccone NL, Grucza RA, et al. Interplay of genetic risk factors and parent monitoring in risk for nicotine dependence. Addiction. 2009;104:1731–40.
82. Johnson EO, Chen LS, Breslau N, Hatsukami D, Robbins T, Saccone NL, et al. Peer smoking and the nicotinic receptor genes: an examination of genetic and environmental risks for nicotine dependence. Addiction. 2010;105:2014–22.
83. Sheehan NA, Didelez V, Burton PR, Tobin MD. Mendelian randomisation and causal inference in observational epidemiology. PLoS Med. 2008;5:e177.